Pharmx FY26收入小增但利润承压，Marketplace高增长尚未转化为盈利

Nvidia Q2 revenue more than doubles, CEO Huang says AI at its ’inflection point’
Introduction & Market Context
Pharmx Technologies Limited (ASX:PHX) presented its FY26 results on August 27, 2026, highlighting strong platform growth across its pharmacy technology ecosystem even as increased investment spending pressured profitability. The company’s shares fell 4.76% to $0.10 following the presentation, leaving the stock trading near the lower end of its 52-week range of $0.084 to $0.20.
The presentation emphasized transformation and strategic positioning, with total revenue reaching $7.74 million, up 3% year-over-year, while the company maintained positive EBITDA of $1.1 million despite significantly higher operating costs tied to its Marketplace launch and strategic partnerships.
Financial Performance Overview
Pharmx delivered mixed financial results in FY26, with revenue growth accompanied by margin compression as the company invested heavily in new platform capabilities. The following chart illustrates the company’s key financial highlights for the period.
Total revenue increased 3% to $7.74 million, with recurring revenue growing 9% on a comparable basis excluding structural market changes. The company’s gross margin improved to 84%, up 2 percentage points from FY25, reflecting a favorable shift in revenue mix away from rebate-based income.
However, profitability metrics weakened as operating costs rose 12% to $6.66 million. EBITDA declined 33% to $1.1 million from $1.6 million in the prior year, while net profit after tax deteriorated to a loss of $1.83 million from a $264,000 loss in FY25. The company attributed this to planned investments in employee benefits, marketing, technology infrastructure, and professional fees related to the Marketplace launch and its strategic alliance with Sigma Healthcare.
As detailed in the company’s profit and loss statement, share-based payments surged 430% to $1.17 million, while professional fees increased 87% to $846,000.
Despite the earnings pressure, Pharmx maintained positive operating cash flow of $825,000, down from $1.77 million in FY25 when excluding prior-year legal settlements. The company ended the period with a cash balance of $2.6 million, down 38% from $4.2 million, after investing $2.1 million in product development.
Platform Growth Metrics
The presentation emphasized strong underlying platform performance across multiple dimensions, with particularly impressive gains in the company’s newer business lines. The following overview illustrates Pharmx’s three-pillar platform strategy.
Pharmx’s core EDI Gateway business, which connects 99% of ANZ pharmacies and processes over $20 billion in annual gross transaction value, saw revenue increase 8% year-over-year. The platform handled more than 300 million invoice lines across 120,000+ products from all major wholesalers and suppliers.
The company’s Marketplace offering, launched during FY26, emerged as a key growth driver with revenue surging 73%. New Zealand operations expanded rapidly with 67% revenue growth, while the Data & Analytics segment increased 25%. These metrics demonstrate the company’s success in diversifying revenue streams beyond its traditional Gateway subscription model.
Platform engagement metrics showed broad-based strength, as illustrated in the following performance dashboard.
Total gross transaction value across the platform increased 11%, while order volumes rose by the same percentage. Average revenue per user (ARPU) expanded across all three business segments, with Gateway ARPU up 10%, Marketplace ARPU surging 69%, and Analytics ARPU growing 12%.
The company also made progress in migrating suppliers to its integrated Single Platform, with 64% of suppliers now using either the Marketplace or full platform integration, up from 60% in FY25—representing a 13% year-over-year improvement in supplier transition.
Marketplace Momentum Builds
The Marketplace segment showed particularly strong momentum in the second half of FY26, with acceleration continuing through the end of the fiscal year. The following chart demonstrates the platform’s rapid scaling trajectory.
Marketplace gross transaction value increased 304% year-over-year, while order volumes more than doubled with 108% growth. Monthly metrics showed consistent improvement, with both GTV and average spend per pharmacy rising sharply from November 2025 through July 2026.
Importantly, a target cohort of engaged users demonstrated high retention and frequency metrics. This group achieved a 77% monthly repeat purchase rate and averaged 17.7 monthly purchases in Q4 FY26. Even across the total user base, the monthly repeat purchase rate reached 49%, with purchase frequency growing 69% from Q3 to Q4.
Management highlighted that the Marketplace had been in market for less than six months and characterized the growth as evidence of product quality and increasing customer trust.
Strategic Initiatives
Pharmx outlined several strategic developments completed or initiated during FY26 that management believes position the company for accelerated growth. The following slide details the foundational elements established during the year.
The strategic alliance with Sigma Healthcare emerged as a centerpiece initiative, with management describing a "strong pipeline of strategically aligned initiatives" scheduled to come online in FY27. The partnership involves a vertically integrated electronic data interchange solution supporting Sigma’s distribution operations, including its New Zealand distribution center.
Other key initiatives included core EDI service modernization with vertical expansion into new product categories, continued supplier additions and platform migrations to improve efficiency, expansion of service partner relationships with contracted growth already secured, and strengthened leadership capabilities with increased AI deployment to reduce costs and accelerate delivery.
CEO Tom Culver stated the company is "very comfortable with the position that we are in" and emphasized that FY26 investments built "some very solid foundations" for future expansion.
Market Position & Industry Trends
Pharmx’s presentation emphasized its central position within the Australian and New Zealand pharmacy ecosystem, connecting thousands of pharmacies with hundreds of suppliers and IT vendors. The following network diagram illustrates the company’s comprehensive market reach.
The company highlighted several favorable industry trends supporting its growth strategy, as detailed in the following market analysis.
Demographic tailwinds include 15.4 million Australians living with chronic conditions (61% of the population) and a projected near-doubling of Australians aged 65+ by 2042. The pharmacy and medicines market continues expanding, with 335 million PBS/RPBS scripts dispensed in 2024-25 and the overall Australian pharmacy retail market forecast to reach $65.7 billion by 2034.
Importantly, approximately 50% of pharmacy purchases now come from front-of-shop retail categories like cosmetics and personal care, expanding Pharmx’s addressable market beyond traditional pharmaceutical products. Australia’s e-pharmacy market is projected to grow at a 12.9% compound annual growth rate from $3.4 billion in 2025 to $10.5 billion by 2034.
Regulatory changes expanding pharmacist scope of practice and shifting consumer demographics—with under-35s now the top-spending pharmacy beauty shoppers—further support the company’s marketplace and analytics strategies.
FY27 Outlook & Execution Priorities
Management characterized FY27 as "a year of execution," outlining specific targets and initiatives expected to drive revenue and margin expansion. The following strategic roadmap details the company’s key focus areas.
Pharmx set an ambitious target of achieving a $100 million annualized Marketplace GTV run rate, up from approximately $56 million annualized based on July 2026’s $4.7 million monthly run rate. The company plans to expand margins by pursuing contract renewals on more than $200 million in available GTV.
EDI modernization and vertical expansion includes adding 40+ new suppliers across Australia and New Zealand. The Sigma alliance will focus on anchor distribution across Australia’s largest pharmacy footprint, while data and analytics initiatives target partnership-led solutions to increase data-as-a-service revenue.
For New Zealand specifically, supplier growth aims to expand market exposure through Bargain Chemist and TONIQ partnerships, with vertical integration in partnership with Sigma providing a foundation for further regional expansion.
Additional revenue drivers expected to come online in FY27 include marketing and advertising income, demand planning and forecasting services, and master data management offerings. Management also projected an 18% reduction in cloud services costs and expects a $1.2 million R&D tax refund in the first half of the year.
Investment Considerations
The presentation highlighted significant operational progress and strategic positioning, but investors appeared to focus on near-term profitability challenges and execution risk. At the current share price of $0.10, Pharmx trades at a market capitalization of approximately $69.9 million with an enterprise value of $67.3 million after accounting for its $2.6 million cash position and no debt.
Key risks include execution challenges in scaling the Marketplace while converting activity into higher revenue, continued pressure from operating costs rising faster than revenue, a reduced cash balance that limits financial flexibility, customer concentration risk from supplier model changes, and adoption risk as the Marketplace requires more suppliers and active pharmacies to reach scale.
However, the company’s dominant position connecting 99% of ANZ pharmacies, strong platform engagement metrics showing double-digit growth across key indicators, successful early traction in the Marketplace with triple-digit revenue growth, and favorable long-term industry trends provide potential upside if management can execute on its FY27 priorities.
The stock’s position near its 52-week low suggests investor skepticism about the timeline for translating platform growth into sustainable profitability, even as the company maintains that its investment year has established the foundation for accelerated expansion ahead.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.